# Verixa — Investor Memo
## The AI-Governed QMS Platform for Regulated Pharma and Biotech

**Company:** Navira Technologies, Inc (US) · Navira Regulatory Technologies Pvt Ltd (India)
**Platform:** Verixa
**Founder/CEO:** Vimal Veereshwarayya, RAC — 16+ years in pharma clinical quality and GxP (Genentech, MyoKardia/BMS, Arcellx, Alumis)
**Stage:** Architecture-complete · pre-validation · pre-revenue · seeking seed
**Prepared:** May 2026

---

> **Use this memo as the source content for the investor slide deck.** Each `##` section maps to one slide. Each table or bullet block is sized to fit a single deck panel. Speaker-notes language is in plain prose under each section.

---

## Slide 1 — One-Line Thesis

**Verixa is the AI-governed Quality Management System for pharma and biotech — built from day one for the regulatory world that begins August 2, 2026.**

That date is when the EU AI Act fully applies to high-risk AI systems, including AI used in pharma manufacturing ([EU AI Act implementation timeline](https://artificialintelligenceact.eu/implementation-timeline/)). Every legacy eQMS — Veeva, MasterControl, TrackWise — was architected before AI governance became a regulated GxP object. Verixa was architected after.

---

## Slide 2 — The Catalyst: Five Regulatory Events in 12 Months

Five independent regulatory events between July 2025 and April 2026 have made AI governance inside the quality record a hard inspection requirement — not a productivity choice.

| Date | Event | Why it matters |
|---|---|---|
| Jul 2025 | **EU GMP Annex 22** draft on AI in GMP published; consultation open to Oct 2025 ([EC Health Document](https://health.ec.europa.eu/document/download/5f38a92d-bb8e-4264-8898-ea076e926db6_en?filename=mp_vol4_chap4_annex22_consultation_guideline_en.pdf)) | Static deterministic AI only in critical apps; GenAI/LLMs prohibited in critical GMP paths; HITL mandatory |
| Aug 2025 | **EU AI Act GPAI rules + penalties** enforceable ([Gardner Law](https://gardner.law/news/eu-ai-act-compliance-timeline)) | Fines up to €35M or 7% of global turnover |
| Jan 2026 | **FDA + EMA joint "Good AI Practice in Drug Development"** ([Jones Day](https://www.jonesday.com/en/insights/2026/01/ema-and-fda-align-on-good-ai-practice-in-drug-development)) | 10 principles: human-centric, ALCOA+, lifecycle, traceability |
| Feb 2026 | **FDA CSA final guidance updated** ([FDA](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-management-system-software)) | Risk-based validation expectations for production/QMS software including AI/ML |
| Apr 2026 | **First FDA warning letter** citing AI overreliance in pharma manufacturing ([Morgan Lewis](https://www.morganlewis.com/blogs/asprescribed/2026/04/fdas-warning-letter-suggests-growing-scrutiny-of-ai-overreliance), [ECA Academy](https://www.gmp-compliance.org/gmp-news/use-of-ai-agents-leads-to-the-first-fda-warning-letter-relating-to-ai)) | AI used for specs, SOPs, MPR/MBR without QU review = 21 CFR 211.22(c) violation |

**Aug 2, 2026** — full EU AI Act application to all high-risk AI systems begins ([EU implementation timeline](https://artificialintelligenceact.eu/implementation-timeline/)). This is the slide-deck "why now."

---

## Slide 3 — The Problem

Pharma quality teams have started using AI before their quality systems can prove AI was governed correctly.

AI now drafts deviation investigations, summarizes CAPAs, classifies complaints, identifies OOS/OOT signals, and retrieves inspection evidence. The compliance question is no longer *whether* AI can assist quality teams. The question is whether a company can prove, under inspection, exactly **which model produced what output, on what input, reviewed by which authorized human, accepted or rejected with which e-signature**.

Legacy eQMS audit trails capture **user actions on workflow records**. They were not designed to capture **model version, prompt hash, retrieved evidence, confidence display, AI output classification, human acceptance/rejection, and model-change control** as first-class GxP objects.

The FDA April 2026 warning letter is the first proof that this gap is now an enforcement risk, not a theoretical one.

---

## Slide 4 — The Solution: Verixa

Verixa is positioned as an **AI-governed pharma QMS** — not a generic modern eQMS. AI governance is embedded into the product architecture, not appended as a policy document or optional settings layer.

**Verixa Phase 1 launch scope:** controlled design-partner evidence workflow + AI-governed QMS core, with phase-gated expansion into the broader GxP suite.

**Verixa architecture commitments** (from internal URS, May 2026):

- Advisory-only AI in regulated workflows; autonomous AI decisions prohibited in critical quality paths
- Human-in-the-loop gates with authority profiles, segregation of duties, e-signature for every regulated decision
- Immutable audit trail of model version, prompt, retrieved evidence, AI output, human acceptance/rejection
- Built-in evidence pack generator for inspection readiness
- Phase-gated module rollout: core eQMS → OOS/OOT, deviations, CAPA, complaints, inspections → batch records, stability, environmental monitoring, APQR → GMP/GDP/MIRA orchestration

This is exactly what FDA's April 2026 warning letter demanded as the corrective action standard, and what EU GMP Annex 22 codifies for the GMP environment.

---

## Slide 5 — Product: The Validated Agent Library

Ketryx proved that the buyer in regulated industries wants a **catalog of validated AI agents**, not a monolithic AI feature. Their May 2025 launch of six GA agents drove the Series B six months later ([Ketryx AI Agents blog](https://www.ketryx.com/blog/ketryx-ai-agents)).

Verixa's pharma-equivalent agent library, mapped from regulated workflow patterns:

| Verixa Agent | Pharma GxP Function | Regulation Anchor |
|---|---|---|
| **Deviation Agent** | Drafts deviation investigation, classifies severity, suggests root cause hypothesis — human QU approves | EU GMP Ch. 1, 21 CFR 211.192 |
| **CAPA Agent** | Tracks CAPA effectiveness, flags overdue actions, recommends closure criteria | 21 CFR 211.192, ICH Q10 |
| **Change Control Agent** | Analyzes change impact across documents, validation state, regulatory commitments | 21 CFR 211.100, ICH Q10 |
| **Complaint Agent** | Triages complaints, classifies criticality, flags MDR/AE signals | 21 CFR 211.198 |
| **OOS/OOT Agent** | Detects out-of-spec/out-of-trend patterns; drafts initial investigation | 21 CFR 211.192, USP <1010> |
| **Annual Product Review Agent** | Auto-assembles APQR from batch records, deviations, complaints, stability | 21 CFR 211.180(e) |
| **Inspection Readiness Agent** | Generates inspection evidence pack on demand with full traceability | EU GMP Annex 15, FDA QSIT |
| **Regulatory Intelligence Agent** | Monitors CDSCO/FDA/EMA changes, flags impact on SOPs | Continuous regulatory monitoring |

Every agent operates with redlines, HITL approval, and full audit trail of model+prompt+evidence — the architecture pattern Ketryx used to win 4 of the top 5 MedTech companies ([Ketryx blog](https://www.ketryx.com/blog/building-the-infrastructure-for-regulated-ai-announcing-ketryx-39m-series-b)).

---

## Slide 6 — Market

**Layered TAM, all verified against primary sources.**

| Layer | 2025 | 2030 | CAGR | Source |
|---|---|---|---|---|
| Pharmaceutical QMS software | $1.59B | $2.98B | 13.3% | [MarketsandMarkets](https://www.marketsandmarkets.com/PressReleases/pharmaceutical-quality-management-software.asp) |
| Life sciences QMS software | $3.55B est. | $6.72B (2030) | 12.99% | [Grand View Research](https://www.grandviewresearch.com/press-release/global-life-sciences-quality-management-software-market) |
| Broader QMS software | $10.0B (2024) | $16.2B | 8.3% | [Verdantix](https://www.verdantix.com/venture/report/market-size-and-forecast--qms-software-2024-2030-global) |
| AI governance market | $185.5M (2025) | $3.59B (2034) | 39.0% | [Dimension Market Research](https://dimensionmarketresearch.com/report/ai-governance-market/) |

**Verixa SOM — India anchor wedge:**

| Indicator | Value | Source |
|---|---|---|
| India USFDA-approved pharma plants (most outside US) | **262+** | [LinkedIn / Anand Gond, Apr 2025](https://www.linkedin.com/pulse/india-leads-most-usfda-approved-pharma-plants-outside-anand-gond-uudlc) |
| India WHO-GMP approved plants | ~1,400 | Same |
| India pharma manufacturing units | 10,500+ | [PIB, Mar 2026](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2243248) |
| India pharma exports FY25 | $30.4B | [IBEF](https://www.ibef.org/exports/pharmaceutical-exports-from-india) |
| India CDMO market 2024 → 2033 | $7.9B → $15.4B | [PharmaSource, Jul 2024](https://pharmasource.global/content/indias-cdmo-market-set-to-double-in-the-next-5-years/) |
| FDA inspections of Indian sites CY2024 | 256 | [CareEdge, Jun 2025](https://www.careratings.com/uploads/newsfiles/1750843740_Indian%20Pharma%20-%20CareEdge%20Report.pdf) |

India's revised Schedule M GMP enforcement wave ([ET Pharma, Mar 2025](https://pharma.economictimes.indiatimes.com/news/regulatory-update/cdsco-begins-online-registration-for-securing-revised-schedule-m-extension-deadline-may-2025/119450865)) forces 10,500+ manufacturing units to upgrade QMS documentation and data integrity in a market structurally unserved by US/EU-priced incumbents like Veeva and MasterControl.

---

## Slide 7 — Category Proof: Investors Are Funding This

| Company | Round | Date | Amount | Lead | Lane |
|---|---|---|---|---|---|
| **Ketryx** | Series B | Sep 2025 | **$39M** | Transformation Capital | MedTech AI compliance |
| Vanta | Series D | Jul 2025 | $150M | Wellington Management | IT compliance (SOC 2, AI Act) — $4.15B valuation |
| Dot Compliance | Series B extension | Apr 2024 | $17.5M | IGP, Vertex | Pharma QMS on Salesforce |
| Aizon | Series C | Feb 2024 | $20M | NewVale Capital | Pharma manufacturing AI |
| Scilife | Growth equity | Jun 2024 | Undisclosed | Five Elms Capital | Pharma/biotech eQMS |
| Brellium | Series A | Apr 2025 | $16.7M | First Round, Left Lane | Healthcare clinical quality AI |
| Entvin AI | Seed | 2025 | $500K | Y Combinator | FDA pharma regulatory AI |
| Ritivel | YC W26 | Jan 2026 | Undisclosed | Y Combinator | Pharma FDA submissions AI |

Sources: [Ketryx Series B](https://www.ketryx.com/press-release/series-b); [Vanta Series D](https://fintech.global/2025/07/24/trust-tech-leader-vanta-bags-150m-to-scale-ai-platform/); [Dot Compliance](https://www.mobihealthnews.com/news/ai-driven-eqms-company-dot-compliance-scores-175m); [Aizon Series C](https://www.businesswire.com/news/home/20240208083122/en/Aizon-Secures-$20M-in-Series-C-Funding-Led-by-NewVale-Capital-to-Enhance-Pharma-Manufacturing-Outcomes); [Brellium Series A](https://www.fiercehealthcare.com/ai-and-machine-learning/startup-brellium-picks-167m-scale-ai-medical-chart-reviews); [Scilife / Five Elms](https://www.prnewswire.com/news-releases/scilife-secures-growth-investment-from-five-elms-capital-to-propel-smart-quality-innovation-302167145.html).

**The category is funded across every adjacent lane. The pharma GxP eQMS lane — Verixa's lane — has the largest TAM and the fewest AI-native challengers.**

---

## Slide 8 — Lead Comparable: Ketryx

Ketryx is the single most important proof point for the Verixa investment thesis.

| Dimension | Ketryx | Implication for Verixa |
|---|---|---|
| Total raised | ~$55–57M across Seed I/II → Series A → Series B in 4 years ([Sourcery VC](https://www.sourcery.vc/p/breaking-ketryx-raises-39m-series)) | Category supports rapid step-up rounds |
| Series B speed | Closed in **14 days** ([Sourcery VC](https://www.sourcery.vc/p/breaking-ketryx-raises-39m-series)) | High investor conviction once category proven |
| Top investors | Transformation Capital (lead Series B), Lightspeed (lead Series A), MIT E14 Fund, Ubiquity Ventures, Bill Hawkins (ex-Medtronic CEO) | Roadmap of target investors for Verixa |
| Traction claims (verified) | 4 of top 5 MedTech cos; Meta as customer; 2% of all 2024 FDA AI/ML approvals; 100M patients reached ([YouTube / The Lantern, Apr 2026](https://www.youtube.com/watch?v=4zYgIW8Ew60)) | Validates the "AI compliance for regulated product development" investment thesis |
| Validated AI agents (GA May 2025) | 6 agents: Requirement Conflict, Redundancy, Test Coverage, Anomaly Review, Change Request, Complaint ([Ketryx AI Agents](https://www.ketryx.com/blog/ketryx-ai-agents)) | Roadmap pattern for Verixa's agent library |
| Certifications | UL-issued IEC 62304, ISO 13485, ISO 14971 (Mar 2024); SOC 2 Type II; HIPAA; 21 CFR Part 11 ([Ketryx](https://www.ketryx.com/blog/announcing-ketryxs-ul-certification)) | Third-party certification is a credibility prerequisite — Verixa target list |
| Regulatory lane | MedTech / SaMD only (IEC 62304, ISO 13485, EU MDR) | **Pharma GMP is unaddressed — Verixa's open whitespace** |
| India presence | None | India is Verixa's structural wedge |

**Speaker note:** Ketryx is the strongest available proof that institutional venture capital will write large checks into AI-native compliance infrastructure for regulated industries. Verixa applies the same architecture thesis to a larger, more fragmented, less-penetrated market: pharma GxP.

---

## Slide 9 — Why Not Ketryx?

The investor's first objection will be: *"why won't Ketryx just expand into pharma?"*

| Defensibility axis | Ketryx | Verixa |
|---|---|---|
| **Regulatory grammar** | IEC 62304 SDLC + ISO 14971 risk + 21 CFR 820/QMSR | ICH Q7/Q9/Q10, EU GMP Annexes 1/11/15/22, 21 CFR 210/211, Schedule M |
| **System-of-record integrations** | Jira, GitHub, Azure DevOps, Jama, TestRail, BitBucket | Veeva Vault, MasterControl, TrackWise, LIMS (LabWare, STARLIMS), MES, SAP QM |
| **Buyer persona** | VP Engineering / Head of SQA at MedTech | Head of QA / Qualified Person / Plant Quality Head at pharma site |
| **Sales motion** | US/EU MedTech | India + global pharma + CDMO |
| **AI governance lane** | SaMD safety-critical software lifecycle | GMP manufacturing AI — explicit Annex 22 scope |
| **Compliance certifications** | UL — IEC 62304, ISO 13485, ISO 14971 | Target: ISO 9001, EU GMP Annex 11/22, 21 CFR Part 11, Schedule M alignment |
| **Geographic footprint** | US-headquartered, no India presence | Dual-entity: Navira Technologies Inc (US) + Navira Regulatory Technologies Pvt Ltd (India) |

Ketryx's $55M+ war chest could fund a pharma lane attempt — but the standards, integrations, buyer, and certification paths do not transfer. Greenlight Guru raised $120M in 2021 and has not entered pharma in five years; Veeva has not entered MedTech SaMD compliance. **Regulated software lanes do not cross-port.**

---

## Slide 10 — Competitive Landscape (One-Glance)

| Vendor | Founded | Total Funding | Lane | AI-Native? | India Presence |
|---|---|---|---|---|---|
| **Veeva Vault QMS** | 2007 | Public, NYSE:VEEV | Pharma eQMS | Retrofit | Yes (sales) |
| **MasterControl** | 1993 | $150M @ $1.3B (Dec 2022) | Pharma + MedTech | Retrofit | Yes |
| **Honeywell Sparta TrackWise** | 1994 (acq. Dec 2020) | Acquired | Pharma + MedTech | Limited | Yes |
| **Qualio** | 2015 | $65M (Tiger Global Series B) | Pharma/MedTech SMB | Modern but not AI-governed | No |
| **Dot Compliance** | 2018 | ~$50M | Pharma/MedTech on Salesforce | **AI-first** | No |
| **Scilife** | 2015 | Five Elms growth equity Jun 2024 | Pharma/IVD eQMS | "Smart Quality" KPIs | No |
| **AmpleLogic** | 2013 | Bootstrapped | Pharma manufacturing | Limited | Yes (HQ Hyderabad) |
| **Caliber Technologies** | 2009 | Bootstrapped | India pharma QMS | Limited | Yes (HQ India) |
| **Ketryx** | 2021 | ~$55–57M | MedTech / SaMD AI | **AI-native** | No |
| **Verixa (Navira)** | 2025 | Pre-seed | **Pharma GxP AI-governed** | **AI-native from architecture** | **Dual-entity US+India** |

Sources per Section 2 of [research dossier](#).

**Competitive thesis:** Incumbents are stronger on inspection history and module maturity. They are weaker on AI governance embedded into the GxP record, and structurally weaker on India-specific compliance. Dot Compliance is the closest AI-native pharma comparable but is Salesforce-locked and has no India footprint.

---

## Slide 11 — Go-To-Market: The Two-Lane India Design-Partner Motion

Phase 1 will NOT be sold as "full GxP suite replacement." That overclaims and invites direct comparison with Veeva where Verixa has no inspection history.

**Phase 1 GTM motion:** controlled design-partner evidence workflow.

| GTM choice | Recommendation |
|---|---|
| Initial buyer | Joint Head of Quality / Digital Quality / Pharma 4.0 sponsor |
| Lane A ICP | Early-stage biotech / ATMP / cell therapy with AI governance anxiety, minimal incumbent lock-in (founder's clinical-quality network at Alumis, Arcellx, MyoKardia is the warm intro engine) |
| Lane B ICP | Indian CDMO / specialty pharma facing Schedule M revised enforcement and USFDA inspection pressure |
| Initial use case | AI-governed QMS evidence workflow: audit trail, HITL, e-signature, controlled AI refusal, inspection-readiness pack |
| Commercial model | $25K–$75K design-partner / pilot pricing, services-heavy validation support |
| Expansion path | Phase-gated rollout into broader GxP modules after validation review and customer usage proof |

**The first demo leads with the differentiator: the AI layer refusing to finalize or write into a regulated decision path without proper human authority, e-signature, audit trail, and approval context. The refusal is the product story.**

---

## Slide 12 — Traction & 12-Month Milestones

Verixa is pre-validation. The honest framing is "architecture-complete, validation-stage seed," not "traction-backed SaaS." The next funding milestone is **converting URS-backed architecture into customer evidence**, not scale.

| Milestone | Quarter | De-risks |
|---|---|---|
| Phase 1 scope-lock matrix (live / phase-gated / future) | Q3 2026 | Scope overclaim risk |
| URS-to-code traceability review by third party | Q3 2026 | Engineering execution risk |
| 1–2 design-partner LOIs in Lane A (US biotech/ATMP) | Q4 2026 | Market signal |
| 1–2 design-partner LOIs in Lane B (India CDMO) | Q4 2026 | India ICP validation |
| Validation package published (CSA / GAMP 5 Cat 4) | Q1 2027 | Enterprise diligence gate |
| Regulatory advisory board formed (ex-FDA, EMA, CDSCO) | Q1 2027 | Buyer trust |
| 3–5 signed design partners (paid pilots) | Q2 2027 | ICP/feedback loop |
| First customer inspection outcome (any regulator) | Q3–Q4 2027 | The most valuable long-term credibility milestone |

---

## Slide 13 — Team

**Vimal Veereshwarayya — Founder & CEO** ([LinkedIn](https://www.linkedin.com/in/drvvimal))
- RAC-certified; 16+ years in pharma clinical quality and GxP
- Sr. Director GCP/PV at Alumis (2022–2024); Director Clinical Quality at Arcellx (cell therapy, 2021–2022); Director Clinical Quality at MyoKardia/BMS (2019–2021); Strategy Lead — Clinical QA & Risk at Genentech (2008–2015); Clinical Scientist / Regulatory PM at Northwestern Feinberg (2006–2008)
- Domain expertise: 21 CFR Part 11, EU Annex 11, ICH Q9, CAPA, RCA, FMEA, audit-readiness simulation, ATMPs

**Advisory board (in formation):** ex-FDA, ex-EMA, GxP SMEs — closing Q1 2027.

**Key hires planned with seed:**
- VP Engineering (regulated AI / validated systems)
- Head of Validation (GAMP 5, CSA, computer systems validation)
- Head of GTM India (CDSCO / Indian pharma networks)
- 2–3 senior engineers (AI/ML + regulated software)

---

## Slide 14 — IP & Moat

Verixa's moat is architectural and certifiable, not patent-dependent. Three layers:

1. **Architectural moat** — AI governance embedded at schema level (model version, prompt hash, retrieved evidence, HITL gate, e-signature, audit trail as first-class GxP objects). Retrofitting this into Veeva, MasterControl, or TrackWise requires fundamental re-architecture, not module addition.
2. **Certification moat** — target third-party certification against ISO 9001, EU GMP Annex 11/22, 21 CFR Part 11, and Schedule M alignment. Ketryx used UL certification for IEC 62304/ISO 13485/ISO 14971 as a buyer-trust accelerator ([Ketryx UL announcement](https://www.ketryx.com/blog/announcing-ketryxs-ul-certification)); Verixa replicates the playbook in the pharma lane.
3. **Data + design-partner moat** — every design partner generates inspection evidence, validation artifacts, and customer feedback that compounds into a defensible knowledge graph of pharma GxP workflows. Patent filings in process for the AI-governance + audit-trail architecture (filing plan documented separately).

**No conflicting trademark, MCA filing, or domain registration** was found for the Navira name in pharma/regulatory technology globally as of May 2026, per the external public-footprint check.

---

## Slide 15 — The Ask

**Raise:** Seed round structured against a **validation plan**, not a scale plan.

**Use of funds — 18-month runway:**

| Bucket | % | Purpose |
|---|---|---|
| Engineering (4–5 hires) | 45% | Phase 1 launch-scope lock, URS-to-code, agent library v1, validated platform release |
| Validation & certification | 20% | CSA / GAMP 5 Cat 4 validation package, third-party architecture review, Annex 11/22 alignment audit |
| Go-to-market (India + US) | 20% | 3–5 design partners across Lane A + Lane B, Head of GTM India, conference presence |
| Regulatory advisory board | 5% | Ex-FDA / EMA / CDSCO advisors on retainer |
| Founder + ops + buffer | 10% | Dual-entity operating costs, legal (IP), founder draw |

**Milestones unlocked by this raise:**
- Phase 1 validated platform release
- 3–5 paid design partners with signed pilot agreements
- Published validation package + third-party architecture review
- Regulatory advisory board live
- First customer inspection touchpoint
- Seed → Series A readiness story: 5–10 paying customers, validation proof, India + US dual-market signal

---

## Slide 16 — Investor Universe (Target Pipeline)

**India-side seed/pre-Series A:** Blume Ventures (deeptech + healthtech), Chiratae Ventures (AI + healthtech), HealthQuad (healthcare-focused), Kalaari Capital (SaaS + healthtech), Stellaris Venture Partners (B2B SaaS + healthtech). Sources: [Blume Fund V](https://www.facebook.com/Inc42/posts/vc-firm-blume-ventures-has-announced-the-first-close-of-its-fund-v-at-175-mn-abo/1388064406251011/); [Chiratae press](https://www.chiratae.com/category/press-releases/); [HealthQuad](https://www.healthquad.com).

**US/global life-sciences + regulated AI:**
- **Transformation Capital** — led Ketryx Series B; direct category overlap ([Transformation Capital partners](https://transformcap.com/partner-companies))
- **Lightspeed Venture Partners** — led Ketryx Series A
- **Ubiquity Ventures & MIT E14 Fund** — Ketryx seed-stage backers
- **Bessemer Venture Partners** — March 2026 roadmap explicitly names pharma regulatory/manufacturing AI as a target ([Bessemer life sciences AI roadmap](https://www.bvp.com/atlas/roadmap-reinventing-life-sciences-with-ai))
- **General Catalyst** — life sciences software thesis ([GC life sciences](https://www.generalcatalyst.com/stories/the-future-of-life-sciences-investment))
- **a16z bio + health** — pharma AI thesis ([a16z bio + health](https://a16z.com/bio-health/))
- **OrbiMed** — Mumbai office; pharma + health-IT crossover

The strongest first-call list: Transformation Capital, Bessemer, Blume, Chiratae, HealthQuad.

---

## Slide 17 — Risks & Mitigations

| Risk | Investor Concern | Mitigation |
|---|---|---|
| No pilots yet | Market may not validate the thesis | Prioritize design-partner LOIs before broad fundraising narrative; founder's clinical-quality network is the warm-intro engine |
| Scope overclaim | Target-state URS may be mistaken for Phase 1 launch | Publish launch-scope matrix separating live / phase-gated / validation-gated / future / out-of-scope capabilities |
| Incumbent response | Veeva / MasterControl / Dot Compliance can ship AI features | Compete on schema-level governance and regulator-readable provenance — features incumbents cannot retrofit without re-architecture |
| No inspection history | Pharma buyers risk-averse on QMS replacement | Start with controlled evidence workflow, not full replacement |
| Services-heavy early deployments | Gross margin appears weak initially | Treat services as validation enablement; productize documentation over time |
| Annex 22 timing | Annex 22 may evolve or be delayed | Anchor urgency in FDA April 2026 warning letter + EU AI Act Aug 2026 enforcement, both already in force |
| Ketryx encroachment | Ketryx could pivot into pharma | Different regulatory grammar, integrations, buyer, and certifications — non-trivial pivot for Ketryx (see Slide 9) |

---

## Slide 18 — The Investor Pitch in Four Sentences

1. Pharma quality teams have started using AI before their quality systems can prove AI was governed correctly.
2. Five regulators have made that gap an inspection problem between July 2025 and April 2026 — culminating in the EU AI Act's full application on August 2, 2026.
3. Verixa is the AI-governed pharma QMS built for that world: advisory-only AI, human authority gates, e-signature, audit trail, model-prompt provenance, and phase-gated GxP coverage.
4. Ketryx already proved investors will fund this category at $39M Series B — but for MedTech only; Verixa applies the same architecture thesis to the larger, less-penetrated, India-anchored pharma GxP market.

---

## Slide 19 — Bottom Line

> **Verixa is the AI-governed pharma QMS built for regulated AI: architecture-complete, pre-validation, launching through controlled design partners across the US biotech and Indian CDMO markets, and designed to turn AI-assisted quality work into regulator-ready evidence.**

The product is not yet validated by the market. The architecture thesis is timely. The regulatory wedge is real. The category is funded. The India entry point is structurally underserved. The founder's domain credibility is unusual for a seed-stage AI company.

This is a disciplined seed-stage validation campaign — not a scale story. The deck should reflect that.

---

*This memo is research and analysis only and does not constitute investment advice. All figures sourced inline against primary or primary-adjacent sources; full supporting research is in the companion dossier.*